These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30745358)

  • 21. Protein structural and surface water rearrangement constitute major events in the earliest aggregation stages of tau.
    Pavlova A; Cheng CY; Kinnebrew M; Lew J; Dahlquist FW; Han S
    Proc Natl Acad Sci U S A; 2016 Jan; 113(2):E127-36. PubMed ID: 26712030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analyzing Tau Aggregation with Electron Microscopy.
    Huseby CJ; Kuret J
    Methods Mol Biol; 2016; 1345():101-12. PubMed ID: 26453208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding molecular features of aggregation-resistant tau conformer using oxidized monomer.
    Jebarupa B; Mathew B; Srinivasu BY; Sasikumaran A; Joseph S; Mandal AK; Thomas T; Mitra G
    Biochim Biophys Acta Gen Subj; 2019 Jun; 1863(6):993-1005. PubMed ID: 30853336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The protein-surfactant stoichiometry governs the conformational switching and amyloid nucleation kinetics of tau K18.
    Kaur J; Giri A; Bhattacharya M
    Eur Biophys J; 2020 Sep; 49(6):425-434. PubMed ID: 32691116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of Tau amyloid fibril formation by folic acid: In-vitro and theoretical studies.
    Ghasemzadeh S; Riazi GH
    Int J Biol Macromol; 2020 Jul; 154():1505-1516. PubMed ID: 31751728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Catalytic Prion-Like Cross-Talk between a Key Alzheimer's Disease Tau-Fragment R3 and the Type 2 Diabetes Peptide IAPP.
    Arya S; Claud SL; Cantrell KL; Bowers MT
    ACS Chem Neurosci; 2019 Nov; 10(11):4757-4765. PubMed ID: 31642657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases.
    Choi ML; Gandhi S
    FEBS J; 2018 Oct; 285(19):3631-3644. PubMed ID: 29924502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different Positron Emission Tomography Tau Tracers Bind to Multiple Binding Sites on the Tau Fibril: Insight from Computational Modeling.
    Murugan NA; Nordberg A; Ågren H
    ACS Chem Neurosci; 2018 Jul; 9(7):1757-1767. PubMed ID: 29630333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamics of protein aggregation and oligomer formation governed by secondary nucleation.
    Michaels TC; Lazell HW; Arosio P; Knowles TP
    J Chem Phys; 2015 Aug; 143(5):054901. PubMed ID: 26254664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding the kinetic roles of the inducer heparin and of rod-like protofibrils during amyloid fibril formation by Tau protein.
    Ramachandran G; Udgaonkar JB
    J Biol Chem; 2011 Nov; 286(45):38948-59. PubMed ID: 21931162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation and characterization of neurotoxic tau oligomers.
    Lasagna-Reeves CA; Castillo-Carranza DL; Guerrero-Muoz MJ; Jackson GR; Kayed R
    Biochemistry; 2010 Nov; 49(47):10039-41. PubMed ID: 21047142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tau Assembly into Filaments.
    Pérez M; Cuadros R; Medina M
    Methods Mol Biol; 2018; 1779():447-461. PubMed ID: 29886549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zinc Binding to Tau Influences Aggregation Kinetics and Oligomer Distribution.
    Moreira GG; Cristóvão JS; Torres VM; Carapeto AP; Rodrigues MS; Landrieu I; Cordeiro C; Gomes CM
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31783644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary Fibril Nucleation of Aggregation Prone Tau Fragments PHF6 and PHF6.
    Smit FX; Luiken JA; Bolhuis PG
    J Phys Chem B; 2017 Apr; 121(15):3250-3261. PubMed ID: 27776213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Membrane-mediated fibrillation and toxicity of the tau hexapeptide PHF6.
    Fanni AM; Vander Zanden CM; Majewska PV; Majewski J; Chi EY
    J Biol Chem; 2019 Oct; 294(42):15304-15317. PubMed ID: 31439664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection and Quantification Methods for Fibrillar Products of In Vitro Tau Aggregation Assays.
    Nanavaty N; Lin L; Hinckley SH; Kuret J
    Methods Mol Biol; 2017; 1523():101-111. PubMed ID: 27975246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can any "non-specific charge modification within microtubule binding domains of Tau" be a prerequisite of the protein amyloid aggregation? An in vitro study on the 1N4R isoform.
    Jangholi A; Ashrafi-Kooshk MR; Arab SS; Karima S; Poorebrahim M; Ghadami SA; Moosavi-Movahedi AA; Khodarahmi R
    Int J Biol Macromol; 2018 Apr; 109():188-204. PubMed ID: 29248553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dependence of the Formation of Tau and Aβ Peptide Mixed Aggregates on the Secondary Structure of the N-Terminal Region of Aβ.
    Rojas AV; Maisuradze GG; Scheraga HA
    J Phys Chem B; 2018 Jul; 122(28):7049-7056. PubMed ID: 29940109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Under Heparin-Free Conditions Unsaturated Phospholipids Inhibit the Aggregation of 1N4R and 2N4R Tau.
    Ali A; Matveyenka M; Rodriguez A; Kurouski D
    J Phys Chem Lett; 2024 Aug; 15(33):8577-8583. PubMed ID: 39140785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanistic insights into remodeled Tau-derived PHF6 peptide fibrils by Naphthoquinone-Tryptophan hybrids.
    KrishnaKumar VG; Paul A; Gazit E; Segal D
    Sci Rep; 2018 Jan; 8(1):71. PubMed ID: 29311706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.